Health-related quality of life in patients with rheumatoid arthritis

[1] Singh JA(2016)2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol 68 1-26

[2] Saag KG(2017)Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: integrating systematic literature research and expert opinion of the Thai rheumatism association Int J Rheum Dis 20 1142-1165

[3] Bridges SL(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

[4] Katchamart W(2003)Rheumatoid arthritis RN 66 46-52

[5] Narongroeknawin P(2011)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20 1727-1736

[6] Chevaisrakul P(2013)Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study Qual Life Res 22 1717-1727

[7] Smolen JS(2011)Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain Value Health 14 192-200

[8] Landewe R(2016)Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database Mod Rheumatol 26 40-45

[9] Bijlsma J(2016)Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean observational study network for arthritis (KORONA) registry data Rheumatol Int 36 505-513

[10] Veronesi J(2015)Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis Rheumatol Int 35 1693-1699

[1] Singh JA(2016)2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol 68 1-26

[2] Saag KG(2017)Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: integrating systematic literature research and expert opinion of the Thai rheumatism association Int J Rheum Dis 20 1142-1165

[3] Bridges SL(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-977

[4] Katchamart W(2003)Rheumatoid arthritis RN 66 46-52

[5] Narongroeknawin P(2011)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20 1727-1736

[6] Chevaisrakul P(2013)Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study Qual Life Res 22 1717-1727

[7] Smolen JS(2011)Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain Value Health 14 192-200

[8] Landewe R(2016)Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database Mod Rheumatol 26 40-45

[9] Bijlsma J(2016)Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean observational study network for arthritis (KORONA) registry data Rheumatol Int 36 505-513

[10] Veronesi J(2015)Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis Rheumatol Int 35 1693-1699